Journal
JOURNAL OF NEUROLOGY
Volume 257, Issue 9, Pages 1421-1431Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-010-5591-7
Keywords
Tumor necrosis factor alpha (TNF-alpha); Anti-TNF-alpha; Neurological adverse events; Demyelinating disease; Infliximab; Etanercept; Adalimumab
Categories
Ask authors/readers for more resources
Anti-tumor necrosis factor alpha (TNF-alpha) drugs have been successfully used for the treatment of rheumatic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, ankylosing spondylitis (AS), juvenile chronic arthritis, and Crohn's disease. However, they have been associated with different neurological disorders, including alterations of peripheral nerves, multiple sclerosis (MS), optic neuritis (ON) and acute transverse myelitis (ATM). This article reviews the most current aspect regarding neurological adverse events associated with anti-TNF-alpha drugs with emphasis on the possible explanations for this relation and the pathogenic mechanism of TNF-alpha in neurological disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available